Editorial companion

What stands out

Novo Nordisk's shares fell after Chief Executive Officer (CEO) Mike Doustdar refrained from offering concrete turnaround plans following news that Eli Lilly has overtaken it in the fast-growing obesity drug market. The episode singled out management’s muted response at a moment when investors expect a clear strategy; in pharmaceuticals a single therapy can reshape revenues for years. The mismatch between market expectations and messaging explains why the stock moved sharply on the news.